DNAprint Genomics (DNAG)

[Blue Juggernaut]

Off the Harvard Website
Looks like it was from 2002 but its an interesting read considering this months PR.
Big Blue

http://research.bidmc.harvard.edu/TVO/tvotech.asp?Submit=List&ID=579


Treatment for Anemia: Modified and Improved Erythropoietin-Like Proteins

Category: Therapeutics

KeyWords: Chemotherapy;


BIDMC ID: 23


Abstract:


Erythropoietin (EPO) is a hematopoietic growth and differentiation factor that is key to maturation of red blood cells. EPO is produced in specialized kidney cells and the vast majority of patients with end stage renal disease experience anemia due to the inadequate supply of EPO. Several recombinant EPO products are currently used for the treatment of anemia and sales of EPO products topped 6 billion dollars in 2001. This invention describes novel EPO-like fusion proteins. These multimeric forms of EPO display a longer circulating half-life and increased potency. The patents broadly claim methods of increasing the biological activity of any suitable peptide.


Inventor: Dr. Arthur Sytkowski


Commercial Opportunity:


These novel EPO-like fusion proteins are useful for the treatment of anemia experienced by dialysis patients as well as patients receiving chemotherapy.


Competitive Advantages:


The novel EPO-like proteins have a prolonged plasma half-life and a higher potency than other EPO products and thus will likely require less frequent administration.


Related Publications:





State of Development:


BIDMC seeks a corporate partner to aid in the development, including scale up and primate studies, of these proteins.


Related Technology URL:





Patent Status:


US Patent 6,187,564 B1, issued 2/13/01. US Patent 5,919,758 issued 7/6/99. Foreign applications pending.



TVO Contact Info:
Christine Jost-Price
Associate Director TVO
[e-mail]
Phone: [phone] Fax: [phone]

Beth Israel Deaconess Medical Center
Technology Ventures Office Room: FN-218
330 Brookline Avenue
Boston, MA 02215